Please login to the form below

Not currently logged in
Email:
Password:

Nimbus looks to Merck for CEO

Donald Nicholson spent 26 years at US pharma giant

merck donald nicholsonNimbus has appointed Merck & Co's Donald Nicholson as the company's new CEO.

Nicholson spent 26 years at Merck holding various strategic leadership and operational roles in diverse therapeutic areas including respiratory inflammation immunology bone endocrine urology infectious diseases and neurosciences.

He began his career in 1988 at the Merck-Frost Centre for Therapeutic Research in Montreal.

In his new role at Nimbus Nicholson will lead a US biotech with a portfolio of programmes in immunology oncology and metabolic diseases targeting mechanisms that have been traditionally difficult or intractable. The company is expected to enter human clinical trials in early 2015.

It is thrilling to join the company at such a watershed moment as the lead programs move toward clinical development,” said Dr Nicholson. “I look forward to working with such a highly respected team of colleagues Board members and investors to deliver the greatest value of the portfolio to patients.”

1st October 2014

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Report: Achieving launch excellence in the challenging healthcare markets of today
Our in-depth report is based on original data and expert interviews, which coupled with our own experience, ensures we give you the best recommendations for achieving launch success in challenging...
What is blockchain and why should i care - Richard Springham
Four Health - Emerging Technologies The power of blockchain lies in the fact it can prove that a unique event occurred at a certain time with out the need to...
NHS medicines optimisation milestone
Steve How, Paul Midgley and Oli Hudson, of the Wilmington Healthcare Consulting Team, explore the implications of Adalimumab’s recent European patent expiry...

Infographics